Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
published in: Lancet Oncology Commission
date of publication: 2014-02
language: English
main subject: phase III clinical trial, cisplatin, lung cancer
Cites articles 24
Date
Title
Article - wd:Q27852787